Neutralizing epitopes of the SARS-CoV S-protein cluster independent of repertoire, antigen structure or mAb technology
Neutralizing antibody responses to the surface glycoproteins of enveloped viruses play an
important role in immunity. Many of these glycoproteins, including the severe acute …
important role in immunity. Many of these glycoproteins, including the severe acute …
[HTML][HTML] Human monoclonal antibodies against highly conserved HR1 and HR2 domains of the SARS-CoV spike protein are more broadly neutralizing
HA Elshabrawy, MM Coughlin, SC Baker… - PloS one, 2012 - journals.plos.org
Immune sera from convalescent patients have been shown to be effective in the treatment of
patients infected with Severe Acute Respiratory Syndrome Virus (SARS-CoV) making …
patients infected with Severe Acute Respiratory Syndrome Virus (SARS-CoV) making …
[HTML][HTML] Human monoclonal antibody combination against SARS coronavirus: synergy and coverage of escape mutants
J Ter Meulen, EN Van Den Brink, LLM Poon… - PLoS …, 2006 - journals.plos.org
Background Experimental animal data show that protection against severe acute respiratory
syndrome coronavirus (SARS-CoV) infection with human monoclonal antibodies (mAbs) is …
syndrome coronavirus (SARS-CoV) infection with human monoclonal antibodies (mAbs) is …
[HTML][HTML] Human monoclonal antibodies to SARS-coronavirus inhibit infection by different mechanisms
MM Coughlin, J Babcook, BS Prabhakar - Virology, 2009 - Elsevier
SARS-CoV causes an acute infection making targeted passive immunotherapy an attractive
treatment strategy. We previously generated human mAbs specific to the S1 region of SARS …
treatment strategy. We previously generated human mAbs specific to the S1 region of SARS …
Development and characterisation of neutralising monoclonal antibody to the SARS-coronavirus
JD Berry, S Jones, MA Drebot, A Andonov… - Journal of virological …, 2004 - Elsevier
There is a global need to elucidate protective antigens expressed by the SARS-coronavirus
(SARS-CoV). Monoclonal antibody reagents that recognise specific antigens on SARS-CoV …
(SARS-CoV). Monoclonal antibody reagents that recognise specific antigens on SARS-CoV …
Identification and characterization of novel neutralizing epitopes in the receptor-binding domain of SARS-CoV spike protein: revealing the critical antigenic …
Y He, J Li, L Du, X Yan, G Hu, Y Zhou, S Jiang - Vaccine, 2006 - Elsevier
The spike (S) protein of severe acute respiratory syndrome coronavirus (SARS-CoV) is
considered as a major antigen for vaccine design. We previously demonstrated that the …
considered as a major antigen for vaccine design. We previously demonstrated that the …
Identification of an antigenic determinant on the S2 domain of the severe acute respiratory syndrome coronavirus spike glycoprotein capable of inducing neutralizing …
H Zhang, G Wang, J Li, Y Nie, X Shi, G Lian… - Journal of …, 2004 - Am Soc Microbiol
Severe acute respiratory syndrome (SARS) is a life-threatening disease caused by a newly
identified coronavirus (CoV), SARS-CoV. The spike (S) glycoprotein of CoV is the major …
identified coronavirus (CoV), SARS-CoV. The spike (S) glycoprotein of CoV is the major …
[HTML][HTML] Generation and characterization of human monoclonal neutralizing antibodies with distinct binding and sequence features against SARS coronavirus using …
M Coughlin, G Lou, O Martinez, SK Masterman… - Virology, 2007 - Elsevier
Passive therapy with neutralizing human monoclonal antibodies (mAbs) could be an
effective therapy against severe acute respiratory syndrome coronavirus (SARS-CoV) …
effective therapy against severe acute respiratory syndrome coronavirus (SARS-CoV) …
Escape from human monoclonal antibody neutralization affects in vitro and in vivo fitness of severe acute respiratory syndrome coronavirus
B Rockx, E Donaldson, M Frieman… - The Journal of …, 2010 - academic.oup.com
Background. Severe acute respiratory syndrome (SARS) emerged as a human disease in
2002. Detailed phylogenetic analysis and epidemiologic studies have suggested that the …
2002. Detailed phylogenetic analysis and epidemiologic studies have suggested that the …
[HTML][HTML] Substitution at aspartic acid 1128 in the SARS coronavirus spike glycoprotein mediates escape from a S2 domain-targeting neutralizing monoclonal antibody
OW Ng, CT Keng, CSW Leung, JSM Peiris, LLM Poon… - PLoS …, 2014 - journals.plos.org
The Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) is the etiological agent
for the infectious disease, SARS, which first emerged 10 years ago. SARS-CoV is a zoonotic …
for the infectious disease, SARS, which first emerged 10 years ago. SARS-CoV is a zoonotic …
相关搜索
- sars cov neutralizing epitopes
- sars cov antigen structure
- sars cov spike protein
- inactivated sars cov vaccine
- sars cov characterization of novel
- sars coronavirus monoclonal antibody
- aspartic acid monoclonal antibody
- development and characterisation monoclonal antibody
- associated coronavirus sars vaccines
- antibody combination escape mutants
- neutralization determinant sars vaccines
- antigen structure neutralizing epitopes
- sars coronavirus neutralizing antibodies
- spike protein characterization of novel
- sars coronavirus escape mutants
- sars coronavirus development and characterisation